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The phenomenon commonly described as themiddle-age spread is the result of elevated adiposity
accumulation throughout adulthood until late middle-age. It is a clinical imperative to gain a
greater understanding of the underpinnings of age-dependent obesity and, in turn, how these
mechanisms may impact the efficacy of obesity treatments. In particular, both obesity and aging
are associated with rewiring of a principal brain pathway modulating energy homeostasis, pro-
moting reduced activity of satiety pro-opiomelanocortin (POMC) neurons within the arcuate nu-
cleus of the hypothalamus (ARC). Using a selectiveARC-deficient POMCmouse line, herewe report
that former obesity medications augmenting endogenous 5-hydroxytryptamine (5-HT) activity
D-fenfluramine and sibutramine require ARC POMC neurons to elicit therapeutic appetite-sup-
pressive effects. We next investigated whether age-related diminished ARC POMC activity there-
fore impacts thepotencyof5-HTobesitypharmacotherapies, lorcaserin, D-fenfluramine, and sibut-
ramine and report that all compounds reduced food intake to a comparable extent in both chow-
fedyoung lean (3–5monthsold) andmiddle-agedobese (12–14monthsold)maleand femalemice.
We provide a mechanism through which 5-HT anorectic potency is maintained with age, via pre-
served 5-HT–POMC appetitive anatomical machinery. Specifically, the abundance and signaling of
the primary 5-HT receptor influencing appetite via POMC activation, the 5-HT2CR, is not perturbed
with age. These data reveal that although 5-HT obesity medications require ARC POMC neurons
to achieve appetitive effects, the anorectic efficacy is maintained with aging, findings of clinical
significance to the global aging obese population. (Endocrinology 155: 3732–3738, 2014)
Adiposity commonly accumulates with age from earlyadulthood (20years old in humans) through latemid-
dle-age (65 years old in humans). This increase in adipos-
ity has significant health implications; age-related obesity
represents the primary cause of metabolic syndromes (1).
Understanding the mechanisms underpinning age-associ-
ated adiposity has clinical implications both for obesity
treatment and the prevention of chronic obesity-related
comorbidities in the aging population (2).
To date, medications targeting 5-hydroxytryptamine
(5-HT; serotonin) pathways have been among the most
clinically successful obesity treatments (3). These include
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D-fenfluramine, which stimulates 5-HT release/blocks
5-HT reuptake, and sibutramine, which blocks 5-HT/nor-
adrenaline (NA) reuptake. However, both compounds have
beenwithdrawn fromclinical use due to off-target effects (3,
4). Transgenic technology has aided in the identification of
5-HT receptors (5-HTRs) responsible for the therapeutic ef-
fect of 5-HT obesity medications; an effect principally me-
diated via Gq-coupled 5-HT2CRs (3). The therapeutic po-
tential of selective activation of 5-HT2CRs for obesity
treatment was realized in the summer of 2012 with the U.S.
Food and Drug Administration approval of 5-HT2CR ago-
nist lorcaserin (Arena Pharmaceuticals) and its release in
2013.
Over the last decade, a primary mechanism through
which5-HTaction, via5-HT2CRactivation, achieves effects
on appetite and bodyweight has been revealed. Specifically,
D-fenfluramine and 5-HT2CR agonists chiefly elicit appeti-
tive effects through activation of pro-opiomelanocortin
(POMC) neurons (5–10). Brain POMC, a critical mediator
of energy balance, is abundantly expressed in the arcuate
nucleus of the hypothalamus (ARC), and a smaller popula-
tion is localized in the nucleus of the solitary tract (11, 12).
Although the5-HT2CR–POMCaxis represents a critical tar-
get in the clinical treatment of obesity, recent reports dem-
onstrate that endogenous ARC POMC regulation of energy
balance is impaired with aging. In middle-aged mice (12
months old, comparable to a human 40 years old), ARC
POMC neurons display an age-dependent upregulation of
mammalian target of rapamycin (mTOR) signaling, which
functions to reduce POMC neuronal activity, an effect re-
versed by mTOR inhibitor rapamycin (13). Furthermore,
genetic ablation of endogenous inhibitors of mTOR pro-
motedagedcharacteristics inARCPOMCneuronsof young
mice (14, 15). Middle-aged mice also display increased in-
hibitory agouti-related protein drive ontoARCPOMCneu-
rons, which functionally reduced POMC firing rate and de-
creased restingmembrane potential comparedwith younger
mice (16).
Given the importance of POMC in mediating 5-HT’s
appetitive effect, we investigated whether age-associated
perturbed ARC POMC activity thereby reduces 5-HT
compound anorectic potency.
Materials and Methods
Animals
Mice on a C57BL/6 background ex-
pressing enhanced green fluorescent pro-
tein (EGFP) under the control of POMC
regulatory elements (POMC-EGFP mice)
(8, 17), ARC-specific POMC-knockout
mice (POMCfneo/fneo) (12), and wild-type
littermates were maintained on a 12-hour
light, 12-hour dark cycle (lights on at 7:00
AM)withadlibitumaccesstochowdietand
water unless otherwise stated. All experi-
ments were in accordance with the United
Kingdom Animals (Scientific Procedures)
Act 1986.
Body composition
Body composition was compared in
young adult (3.2months9days, n7)
and middle-aged adult (13.1 months 
11 days, n  9) male C57BL/6 mice
(Charles River, UK) using dual-energy x-
ray absorptiometry Lunar PIXImus2
mouse densitometer (General Electric
Medical Systems).
Feeding studies
POMCfneo/fneo and wild-type litter-
mates (males: 3.4 months  7 days,
POMCfneo/fneo 47.3  2.1 g and wild-
type 30.1  1.3 g, n  12; females: 3.1
months 8 days, POMCfneo/fneo 37.9
Figure 1. Selective ARC POMC deficiency prevents the anorectic effects of D-fenfluramine and
sibutramine. A–D, Male (n  6) (A) and female (n  6) (B) wild-type mice (WT) significantly
suppressed 4-hour dark cycle food intake after D-fenfluramine (dFEN) (3 mg/kg ip) and
sibutramine (SIB) (5 mg/kg ip) treatment compared with saline treatment; in contrast, male
(n  6) (C) and female (n  8) (D) littermates devoid of ARC POMC (POMCfneo/fneo) were not
responsive to the anorectic effect of dFEN or SIB (repeated-measures ANOVA: main effect of
treatment, F2,44 11.51, P  .0001; main effect of sex, F1,22 8.18, P  .0001; interaction
between treatment and genotype, F2,44 3.73, P  .032; no interaction between treatment and
sex, F2,44 0.79, P  .460; no interaction between genotype, treatment, and sex, F2,44 0.317,
P  .730; no main effect of genotype, F1,22 0.089, P  .768). Importantly, these data confirm
no difference by genotype in 4-hour food consumption; thereby, the genotypic difference is
specific to the interaction between genotype and treatment. Specifically, WT and POMCfneo/fneo
littermates respond significantly differently to dFEN and SIB. As expected, male mice of both
genotypes consumed a greater quantity of food compared with female littermates. *, P  .05
compared with saline analyzed with repeated-measures ANOVA followed by Tukey’s post hoc
comparisons.
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1.5 g and wild-type 23.1  1.8 g, n  14) and POMC-EGFP
young adult (males: 3.7 months 10 days, 28.1 0.7 g, n 8;
females: 3.4months 14 days, 22.0 0.3 g, n 6), andmiddle-
aged adult (males: 13.1 month  20 days, 34.3  0.7 g, n  9;
females: 13.4 months 12 days, 32.3 0.6 g, n 8) mice were
individually housed for 1 week before experimentation and re-
ceived a habituation ip injection of vehicle 1 day before exper-
imentation. Mice were then treated with vehicle, lorcaserin (8
mg/kg), D-fenfluramine (3 mg/kg), or sibutramine (5 mg/kg) 45
minutes before the onset of the dark cycle (lights on at 7:00 AM
and off at 7:00 PM) and food was removed. At the onset of the
dark cycle, chow pellets were replaced and 3- to 4-hour food
intake measured. These studies were performed using a within-
subjects experimental design, with a minimum of a 3-day treat-
ment-free period.
In situ hybridization histochemistry
Young adult (males: 3.2months 9 days, n 7; females: 3.2
months  3 days, n  7) and middle-aged adult (males: 13.1
month 11 days, n 5; females: 13.3 months 5 days, n 7)
C57BL/6micewere anesthetizedwith pentobarbitone (50mg/kg
ip) and transcardially perfused with diethylpyrocarbonate-
treated PBS followed by 10%neutral buffered formalin (Sigma).
Brains were extracted, immersed in the same fixative overnight,
cryoprotected in 20% sucrose for 24 to 48 hours and then sec-
tioned coronally on a freezing sliding microtome at 25 m.
Tissue was collected in 5 equal series. In situ hybridization his-
tochemistry was conducted using antisense radiolabeled ribo-
probes specific to the mRNA sequences of ht2cr (5-HT2CR) and
Pomc (7, 9, 18, 19). Riboprobes were generated from cDNA
templates by in vitro transcription with a T3 (ht2cr) or SP6
(Pomc) polymerase, according to the manufacturer’s protocol
(Promega and Ambion Inc) in the presence of 35S-labeled UTP.
cRNA riboprobes were diluted to 2  107 cpm/mL in hybrid-
ization solution. Sections were mounted ontomicroscope slides,
air-dried, and exposed to Biomax MR film (Kodak). Density of
ht2cr mRNA and Pomc mRNA was examined in adjacent sec-
tions of brain tissue using densitometry analysis by computing
the integrated density (the sum of the gray values minus back-
ground) using ImageJ (National Institutes of Health). This was
performed at 3 ARC levels (1.46,1.82, and2.30mm from
bregma) and the average integrated density was calculated.
Calcium imaging
Coronal brain slices (180m) containing the ARC (1.58 to
1.94 mm bregma) from male POMC-EGFP young adult (2.8
months 5 days, n 4) andmiddle-aged (11.9months 8 day,
n 4) mice were prepared as previously described (8) andmain-
tained in an artificial cerebrospinal fluid solution containing (in
mM) 126 NaCl, 2.5 KCl, 21.4 NaHCO3, 1.2 NaH2PO4, 10
glucose, 2 Na pyruvate, 1.2 MgCl2, 2.4 CaCl2 (pH 7.3), gassed
with 95%O2 and 5% CO2. Slices were loaded with fura-2 AM
(9.6M, 0.04% pluronic acid, 34°C–36°C for 20 minutes, fol-
lowedby20minuteswashout). Imagingwasperformedat 34°C–
36°C with an Olympus FluoView 1000MPE 2-photon laser-
scanning microscope, equipped with a MaiTai DeepSee laser
(Spectra-Physics) tuned to 790 nm and via an LUMPlanFI/IR
40 (NA 0.8) objective. Images were acquired at a frame rate of
5.4 seconds, and spatial averages of somatic fluorescence were
monitored as agonists were applied to the bath perfusion. Flu-
orescence values (F) were corrected for linear bleaching, back-
ground subtracted, and expressed as F/F baseline.
Drugs
5-HT reuptake inhibitor and releaser D-fenfluramine (Tocris
Biosciences), 5-HT and NA reuptake inhibitor sibutramine
(Tocris Biosciences), and 5-HT2CR agonists
WAY-161,503 ([4aR]-8,9-dichloro-
2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]
quinoxalin-5(6H)-one; Tocris Biosciences)
and lorcaserin (LGM Pharma) were used.
Drugs were dissolved in 0.9% sterile saline
and administered in vivo in a volume of 10
mL/kg body weight (ip).
Data analysis
Datawere analyzedwith paired or in-
dependent t test, 2, or repeated-mea-
sures ANOVA followed by Tukey’s post
hoc tests. For all analyses, significance
was assigned at P  .05. Data are pre-
sented as mean  SEM.
Results
5-HT obesity medication
appetite suppression requires
ARC POMC signaling
We first sought to evaluate the
contribution of ARC POMC to the
appetitive effects of 5-HT obesity
Figure 2. Middle-aged mice display an increase in body weight and fat mass. A–D, Body weight
(t10  5.91, P  .001) (A), percent body fat (t14  3.35, P  .0054) (B), fat mass (t14  3.19,
P  .0072) (C), and lean mass (t14  0.73, P  .49) (D) were assessed in young adult (3–5
months old, n  7) and middle-aged (12–14 months old, n  9) male C57BL/6 mice. Data are
presented as mean  SEM. **, P  .01; ***, P  .001 analyzed with independent-samples
t test.
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medications. Previous reports indicate that D-fenfluramine and
5-HT2CRagonists requiremelanocortin4 receptors topro-
duce effects on appetite (6, 7, 9); however, the role of the
melanocortin system in sibutramine’s appetitive effects
has not been established. Although selective genetic ma-
nipulation of 5-HT2CR expression on POMC neurons il-
lustrates the importance of the subpopulationof 5-HT2CR
expressed with POMC in communicating 5-HT obesity
drug effects (5, 10), these studies manipulate 5-HT2CR
receptor expression, not POMC. Here we probe specifi-
cally whether ARC POMC neurons are required for the
therapeutic effect of 5-HT obesity drugs D-fenfluramine
and sibutramine.
D-Fenfluramine produced a significant reduction in
food intake in male and female wild-type mice (Figure 1,
A and B), but this effect was prevented in discrete ARC-
deficient POMCfneo/fneo littermates (Figure 1, C and D).
Surprisingly, sibutramine, which blocks the reuptake of
both 5-HTandNA, also requiredARCPOMCneurons to
achieve its appetitive effects in male and female mice (Fig-
ure 1, A–D). Our results reveal a necessary mechanism
through which obesity medications D-fenfluramine and
sibutramine achieve their therapeutic appetitive effect, via
activation of ARC POMC neurons.
5-HT compound anorectic potency is maintained
with aging
Given that ARC POMC neuron function is diminished
with age,wenext sought to determinewhether 5-HTcom-
pound anorectic potency is thereby compromisedwith ag-
ing. As expected, middle-aged (12–14 months old) male
mice displayed significantly elevated body weight (Figure
2A), percent body fat (Figure 2B),
and fat mass (Figure 2C), but not
lean mass (Figure 2D), compared
with young adult (3–5 months old)
mice. However, D-fenfluramine (3
mg/kg), sibutramine (5 mg/kg), and
lorcaserin (8 mg/kg) suppressed 3-
hourdark cycle food intake toa com-
parable extent in young adult and
middle-aged male (Figure 3, A, C,
and E) and female (Figure 3, B, D,
and F) POMC-EGFP mice. Food in-
take expressed as percent saline con-
firmed no differences in anorectic ef-
fect by age in mice treated with
D-fenfluramine (male t150.73,P
.24, female t90.07,P .47), sibut-
ramine (male t15  0.45, P  .32,
female t9  0.79, P  .22) or lorca-
serin (male t81.22,P .26, female
t10  0.18, P  .86). These data in-
dicate that diminished ARC POMC
activity in middle-age does not im-
pair 5-HT obesity therapy efficacy.
Preserved ARC POMC and
5-HT2CR appetitive machinery
with aging
Given that 5-HT anorectic effi-
cacy is maintained with aging, we
surmised that it is POMC basal tone
that is compromised with aging, not
the 5-HT2CR and POMC neuroana-
tomical appetitive machinery. We
therefore compared Pomc mRNA
and ht2cr mRNA abundance in
Figure 3. Lorcaserin, D-fenfluramine, and sibutramine anorectic potency is maintained with
aging. A, C, and E, Three-hour dark cycle food intake in male mice aged 3–5 months (t7  4.97,
P  .0018) or 12–14 months (t7  5.21, P  .0013) after D-fenfluramine (dFEN, 3 mg/kg) or
saline (A), in male mice aged 3–5 months (t7  5.30, P  .0053) or 12–14 months (t7  5.00,
P  .0088) after sibutramine (SIB, 5 mg/kg) or saline (C), or in male mice aged 3–5 months (t4 
3.38, P  .028) or 12–14 months (t7  3.40, P  .012) after lorcaserin (LORC, 8 mg/kg) or saline
(E). B, D, and F, Three-hour dark cycle food intake in female mice aged 3–5 months (t7  3.6,
P  .0038) or 12–14 months (t7  3.91, P  .0082) after dFEN (3 mg/kg) or saline (B), in female
mice aged 3–5 months (t5  5.34, P  .0075) or 12–14 months (t5  5.11, P  .0093) SIB (5
mg/kg) or saline (D), or in female mice aged 3–5 months (t11  3.00, P  .012) or 12–14 months
(t5 3.28, P  .022) after LORC (8 mg/kg) or saline (F). Data are presented as mean  SEM.
*, P  .05; **, P  .01 analyzed with paired t test.
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young adult (3–5 months old) and middle-aged (12–15
months old)male and femalemice. Despite observing age-
associated obesity, ARC PomcmRNA (Figure 4, A and B)
andht2crmRNA(Figure 4,CandD)didnot varywith age
in male and female mice. These data suggest that critical
neural components for 5-HT appetite regulation at the
level of gene expression are not reduced with age in par-
allel with weight gain.
To investigate the significance of this finding at the
functional level, we determined whether pharmacological
stimulation of the Gq-coupled 5-HT2CRs was equally ef-
fective in increasing ARC POMC cellular activity in brain
slices from young adult and middle-aged POMC-EGFP
mice. Using 2-photon fluorescence imaging to monitor
changes in intracellular calcium, we observed that
5-HT2CR agonist WAY-161503 (20M) activated a sim-
ilar proportion of ARC POMC neurons in both young
adult and middle-aged mice (Figure 4, E–G). Together,
these data reveal that the density of POMCand5-HT2CRs
expressed on an anatomical level is not altered with aging
and, furthermore, that 5-HT2CR signaling within POMC
neurons is not affected by age. This provides amechanism
through which 5-HT and 5-HT2CR agonist anorectic po-
tency is maintained with age.
Discussion
It is a clinical imperative to gain a greater understanding
of themechanisms underlying age-dependent obesity and,
in turn, how these mechanisms impact the efficacy of obe-
sity treatments. Like adult humans, adultmice accumulate
adiposity with age, in the face of constant environmental
conditions (ie, ad libitum access to the same diet and ex-
isting at a constant temperature). Although the biological
factorsdriving increased fat accumulationwithagearenot
well understood, recent reports reveal age-related mela-
nocortin system remodeling and link these functional
changes with age-associated obesity (13, 16). This age-
related remodeled circuitry could thereby impact the ef-
ficacy of obesity medications requiring melanocortin sys-
tem function to exert therapeutic effects.
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Figure 4. Preserved ARC 5-HT2CR–POMC appetitive machinery. A–D, No age-related differences in ARC gene expression were evident in male
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mouse brain slice illustrating EGFP neurons (green) loaded with fura-2 (red) in the ARC. All fura-2–loaded EGFP neurons (yellow, denoted with
white arrow) were measured for changes in intracellular calcium, an assay of neuronal activation. Scale bar, 50 m. F, Representative trace of
POMC-EGFP neuron increasing intracellular calcium concentrations shown by decreasing fluorescence (F) expressed as F/F to 20M WAY-
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P  .892). Data are presented as mean  SEM, where appropriate. Abbreviation: 3v, third ventricle.
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Here we distill a critical and necessary mechanism re-
sponsible for communicating the anorectic effect of obe-
sity medications D-fenfluramine and sibutramine to ARC
POMC neurons. The mechanistic specificity of the hypo-
phagic effect achieved via this small population of POMC
neurons is remarkable given the wholesale effect on 5-HT
and5-HT/NAbioavailability produced by D-fenfluramine
and sibutramine, respectively. Our findings are consistent
with earlier reports demonstrating that 5-HT depolarizes
and stimulates expression of ARC POMC neurons and
that functional melanocortin 4 receptors (the primary ap-
petitive receptor target of POMC) are required for D-fen-
fluramine and 5-HT2CR agonists to suppress food intake
(7, 9, 20, 21). Subsequent work genetically manipulating
5-HT2CRs expressed in global POMC neurons has em-
phasized the importance of this population of 5-HT2CRs
in 5-HT hypophagia. Specifically, D-fenfluramine and
5-HT2CR appetite suppression is attenuated in 5-HT2CR–
null mice but fully restored in mice with 5-HT2CRs exclu-
sively re-expressed in POMCcells (5). These data are com-
plemented by recent findings that selective inactivation of
5-HT2CRs in POMC neurons abolishes D-fenfluramine
and 5-HT2CR agonist hypophagia (10). Our results reveal
a new level of regional specificity and furthermore indicate
that independent of their expression of 5-HT2CRs, POMC
neurons specifically within the ARC are a critical compo-
nent of the neural circuit through which obesity medica-
tions D-fenfluramine and sibutramine influence appetite.
Given that functional POMC is mechanistically re-
quired for 5-HT pharmacotherapy appetite suppression,
recent reports revealing perturbed POMC function and
melanocortin system remodeling in middle-age presented
the possibility that 5-HT compound anorectic efficacy
may be diminished with age. Specifically, middle-age is
associated with an upregulation in mTOR signaling in
ARC POMC cells, coupled with an age-dependent in-
crease in inhibitory agouti-related protein inputs, which
promotes lower resting membrane potential and reduc-
tion in POMC neuronal activity (13, 16).
Nevertheless, in the present study,we demonstrate that
5-HT compounds suppress feeding with equal potency in
young adult and middle-aged mice. Furthermore, we re-
port that the 5-HT2CR–POMC appetitive machinery is
not compromised with middle-age; both ARC ht2cr and
Pomc abundance is preserved, as is 5-HT2CR signaling in
POMC cells. Specifically, plasma membrane Gq-coupled
5-HT2CRs activate phospholipase C, which hydrolyzes
membrane phosphatidylinositol 4,5-bisphosphate into
the second messengers inositol 1,4,5-trisphosphate and
diacylglycerol, promoting calciummobilization (3). Using
2-photon calcium imaging in the ARC of POMC-EGFP
mice, we report that a 5-HT2CR agonist was equally ef-
fective in stimulating intracellular calciummobilization in
young and middle-aged mice, which suggests that there is
no inherent defect in components of the intracellular
signaling cascade lying downstream of the 5-HT2CR.
Thereby, these findings provide a mechanism through
which 5-HT medication anorectic potency is maintained
with age and suggest that pharmacological activation of
the 5-HT2CR-POMC system is sufficient to overcome any
age-related reduction in endogenous POMC neuronal
activity.
In summary, we report that 5-HT compound anorectic
potency is maintained with aging in association with
equivalent 5-HTmedication activation of POMCneurons
at comparable 5-HT2CR densities in the young adult and
middle-aged brain. These data indicate that 5-HT com-
pounds are capable of overcoming components of age-
related changes in physiology to activate POMC neurons
and suppress feeding. These data reveal that although for-
mer and current 5-HT obesity medications require ARC
POMC to achieve appetitive effects, a pathway that is
remodeled with aging, the anatomical 5-HT2CR-POMC
machinery is preserved and the anorectic potency is main-
tained, findings of clinical significance to the global obese
population.
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